HER2-positive advanced breast cancer treatment in 2020

Cancer Treatment Reviews
Marcelle G CescaEvandro de Azambuja

Abstract

HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The development of therapies targeting the HER2 has improved outcomes. The current standard of care, established in 2012 is dual blockade with trastuzumab + pertuzumab as first-line followed by TDM-1 as second-line. Several suboptimal choices are available in third-line or more. In 2019 the presentation of several trials evaluating new drugs and regimens in third-line has re-opened questions about sequencing, treatment of triple positive disease and treatment choice after exposure to TDM-1. These include tucatinib, neratinib and trastuzumab-deruxtecan. Other agents - including other antibody drug conjugates and bispecific antibodies as well as combinations - will lead to further changes in coming years. Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed.

Citations

Oct 22, 2020·Cancers·Maria Francesca Santolla, Marcello Maggiolini
Nov 27, 2020·Expert Opinion on Biological Therapy·Paolo TarantinoGiuseppe Curigliano
Jan 4, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Arlindo R FerreiraEvandro de Azambuja
Jun 4, 2021·Breast Cancer : Targets and Therapy·Lara Ulrich, Alicia F C Okines
Jun 18, 2021·Journal of Cancer Research and Clinical Oncology·Vic HartAlison Tyson-Capper
Jun 22, 2021·Clinical Nuclear Medicine·Narges JokarMajid Assadi
Aug 7, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Shuyi CenWeidong Han
Aug 20, 2021·Breast Cancer Research and Treatment·Luciana de Moura LeiteNoam Falbel Pondé
Sep 12, 2020·Recent Patents on Anti-cancer Drug Discovery·Arunaksharan Narayanankutty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.